Asia-Pacific self-injection market is expected to reach USD 19.43 billion by 2031 from USD 8.51 billion in 2023, growing with a CAGR of 11.1% in the forecast period of 2024 to 2031.
Asia-Pacific Self-injections Market, By Product Type (Self-Injection Devices and Self-Injection Formulation), Dosage Form (Single Dose and Multi-Dose), Route of Administration (Subcutaneous, Intra muscular, and Others), Application (Autoimmune Diseases, Pain Management, Emergency Drugs, Oncology, Hormonal Disorders, and Others), Age Group (Adult, Geriatric, and Pediatric), Gender (Male and Female), Distribution Channel (Direct Tender, Hospital Pharmacy, Online Pharmacy, and Others), Country (China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Indonesia, Australia, Philippines, New Zealand, Taiwan, Vietnam, and Rest of Asia-Pacific) – Industry Trends and Forecast to 2031 Overview of Asia Pacific Self-Injections Market Dynamics: Driver • Rising prevalence of chronic disease Restraint • High cost of self injectors Opportunity • Government initiatives to self-injections Market Players: The key market players operating in the Asia-Pacific self-injection market are listed below: • Novo Nordisk A/S • Johnson & Johnson Services, Inc. • Biogen • Amgen Inc. • Sanofi • AbbVie Inc. • YPSOMED • BD • AstraZeneca • AptarGroup, Inc. • Bayer AG • Bausch Health Companies Inc. • Boehringer Ingelheim International GmBH • F. Hoffmann-La Roche Ltd • GSK plc • Gerresheimer AG • Haselmeier • Ipsen Biopharmaceuticals, Inc. • Lilly • Midas Pharma GmBH • Merck & Co., Inc. • Novartis AG • OVAL MEDICAL TECHNOLOGIES LTD. (SMC LIMITED) • Pfizer Inc. • Philips-Medisize • PharmaJet • Recipharm AB • SCHOTT PHARMA • SHL Medical AG • Société Industrielle de Sonceboz SA • Terumo Corporation • Takeda Pharmaceutical Company Limited • Teva Pharmaceuticals Industries Ltd. • UCB Pharma • West Pharmaceutical Services
1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of Asia-pacific Self-injections Market